Education: MBBS
Professional Bio:
Dr. Abdul Aziz Khan is a General Practitioner who completed his MBBS at the University of Rajasthan. He specializes in the Department of Hematology and Medical Oncology. He is an Assistant Consulta...
This doctor is not available for online consultations on the platform anymore.
Published on Jan 18, 2023 and last reviewed on Jun 19, 2023 - 5 min read
Abstract
Erythropoietin is a vital hormone responsible for the production of red blood cells (RBC) in the bone marrow. Read this article to know more about it.
Introduction
Erythropoietin (EPO) is a crucial hormone or growth factor secreted by the kidneys and the liver (ten percent) that is responsible for the synthesis and maintenance of red blood cells in the bone marrow. EPO (erythropoietin) synthesis is increased in case of cellular hypoxia, and an imbalance in the levels of EPO occurs due to multiple systemic problems like anemia, cancer, chronic, and long-standing kidney diseases.
Erythropoietin (EPO) is a crucial hormone produced primarily by the kidneys, and it regulates the production of red blood cells from the bone marrow. Erythropoietin is classified as a glycoprotein cytokine. This hormone is secreted from the kidneys in response to reduced oxygen levels in the tissue (known as cellular hypoxia). A small amount of erythropoietin is constantly secreted to compensate for physiologic red blood cell turnover; the average lifespan of a red blood cell is one hundred and twenty days, and it is renewed every day. Erythropoietin is produced by interstitial cells of the kidneys; these cells are capable of responding to cellular hypoxia. When the cells reach a sufficient level of oxygen, the production of erythropoietin is reduced. This is an adaptive mechanism of the body.
EPO.
Hematopoietin.
Hemopoietin.
The primary function of EPO is the production and maintenance of red blood cells produced by the bone marrow in response to cellular hypoxia.
Once these red blood cells are produced, EPO also helps in protecting these cells.
Stimulation of differentiation and proliferation of these red blood cells via binding to the erythropoietic receptors.
Initiate the production of hemoglobin (proteins present in the red blood cells that carry oxygen to tissues).
EPO is also known to stimulate vasoconstriction-induced hypertension, the formation of new blood vessels from older vessels, and the promotion of cell survival by activation of EPO receptors.
EPO is mainly produced by the interstitial capillary bed of the renal cortex. About ten percent of EPO is produced in the perisinusoidal cells of the liver. However, the production of EPO by the liver is limited to fetal and perinatal time (the short period immediately before and after childbirth). The gene carrying information about EPO is located on human chromosome 7. Some additional amount of EPO is produced in the multifunctional mural cells (pericytes) of the brain. The regulation of EPO synthesis is primarily based on blood oxygen levels and iron availability. In the absence of hypoxia, the EPO levels are normal, but during hypoxia stress, this level increases about 1000 times. In normal conditions, the promoter gene of EPO is inhibited, whereas, during hypoxia, it is increased to promote the production of EPO.
EPO binds to the receptors present on the cell surface of colony-forming unit-erythrocytes (CFU-E), proerythroblast (precursor cells of erythrocytes), and basophilic erythroblasts in the bone marrow. EPO binding to its receptor leads to the prevention of physiologic apoptosis (programmed cell death).
The normal EPO level is around 10 mU/ml (milliunits per milliliter), and the normal range of EPO is considered to be between 4 to 24 mU/mL. For males, this range is between 5.8 to 9.9 international units per liter, and for females, it is around 6 to 10.6 international units per liter. This normal level of EPO increases up to 1000 mU/mL during hypoxia.
Increased levels of EPO occur when there is prolonged and chronic exposure to low oxygen levels in the tissues. This increased amount of EPO leads to a condition known as polycythemia (high red blood cell count). Excess EPO usually occurs due to the presence of a tumor, and the symptoms of excess EPO include:
Weakness and fatigue.
Dizziness.
Headache.
Itching.
However, these symptoms are non-specific and may be associated with multiple other diseases. In rare cases, excess EPO can be associated with serious health risks like
Increased viscosity of the blood.
Reduced effective blood supply.
Reduced blood oxygenation.
Increased blood pressure in the lungs.
Blood clots.
Lack of EPO leads to reduced red blood cells, which, in turn, leads to anemia. In addition, anemia is the most prevalent complication of reduced EPO. Reduced EPO occurs due to chronic kidney diseases and bone marrow disease. It may also occur due to the presence of some type of cancer in the body. The symptoms of EPO deficiency include:
Fatigue and weakness.
Light-headedness.
Breathlessness.
Pale skin.
Heart palpitations.
EPO levels can be easily tested through blood examination. Blood tests are done like any other regular blood test, and patients generally do not have to prepare for them. The test is done in the following ways:
Blood samples are collected from the veins.
The sample is usually collected in the morning.
The patient should fast for eight to nine hours (overnight) before the test.
Sometimes, the doctor may advise a complete blood count to be done before EPO testing.
The collected sample is sent to the laboratory to check for the level of EPO present in the blood.
The patient should inform their healthcare provider if they are taking drugs or supplements before going for the test.
Recombinant human erythropoietin is an erythropoiesis-stimulating agent that is used for various diseases that cause a reduction in red blood cell count. Recombinant erythropoietin is used for the treatment of chronic anemia, kidney diseases, cancer, and human immunodeficiency virus infection (HIV). It is marketed in three forms:
Epoetin ɑ.
Epoetin β.
Epoetin δ.
Epoetin Ω.
These drugs can be given in the form of injections.
The use of recombinant erythropoietin by athletes to improve their performance is very common malpractice, and it is known as erythropoietin doping. EPO doping exponentially increases the number of red blood cells, which eventually increases the oxygen concentration in the muscles. This increased oxygen supply to the muscles helps athletes in performing abilities and endurance. However, this doping is illegal and banned in all professional sports in all countries. The International Olympics committee banned EPO doping in the year 1990. Two philosophies are developed to detect recombinant human EPO in the blood; the first is based on indirect blood markers, and the second is based on the direct detection of recombinant human EPO in the urine.
Conclusion
The use of recombinant EPO has been constantly misused by athletes and sports professionals to enhance and improve their performance. However, EPO doping has been strictly prohibited all over the world in every professional sport. Athletes have to undergo various screenings before the competition to get their serum EPO levels checked.
A neoplastic clonal blood condition called polycythemia vera causes red blood cells to proliferate independently. Since erythropoietin controls the development of red blood cells, an increase in red blood cells results in a negative feedback suppression of erythropoietin. Extremely high levels of hemoglobin or hematocrit (volume of red blood cells) and low serum erythropoietin levels are seen in patients with polycythemia vera.
In the kidney, interstitial fibroblasts are associated with the proximal convoluted tubule and peritubular capillaries to create erythropoietin. Additionally, it is produced in the perisinusoidal cells of the liver. In the prenatal and postnatal stages, liver production is predominant; in adulthood, renal production is predominant. Erythropoietin can be increased; for example, Echinacea, a herb considered to increase the blood's ability to transport oxygen, is believed to increase erythropoietin levels. Furthermore, erythropoietin levels are also increased by increasing dietary iron and exercising.
Anemia is a disorder that occurs when the blood produces fewer healthy red blood cells than is typical. The body does not receive enough oxygen-rich blood if one has anemia. One may feel exhausted or weak due to a lack of oxygen. Hypoxia, or a lack of oxygen, stimulates erythropoietin production, especially in the kidneys.
Erythropoietin is a naturally occurring glycoprotein hormone that promotes erythropoiesis (red blood cell production), erythrocyte maturation, and erythrocyte proliferation. Erythropoietin is used by the body to regulate the number of circulating erythrocytes and keep tissue oxygen delivery levels within a certain range. Thus, erythropoietin has been demonstrated to improve performance metrics, including time till fatigue and maximum oxygen consumption.
Recombinant human erythropoietin is a biopharmaceutical medication used to treat anemia, cancer, and chronic kidney disease in individuals with low hemoglobin levels. Endogenous erythropoietin or its recombinant analogs connect to cells and initiate a cascade of cellular communication that turns on genes that encourage cell growth and inhibit apoptosis. As a result, hematocrit and total body hemoglobin are stimulated to rise.
By artificially raising erythropoietin levels, one can boost the quantity of oxygen given to tissues, especially muscles, by producing more hemoglobin and red blood cells. Whereas high quantities of red blood cells can result from too high erythropoietin levels leading to polycythemia.
A hormone called erythropoietin is produced by healthy kidneys and encourages the bone marrow to manufacture the red blood cells required to transport oxygen throughout the body. Erythropoietin is a glycoprotein growth factor that the kidney produces to control the bulk of red blood cells, principally through promoting the development, maturation, and differentiation of erythroid progenitor cells. The majority of the hypoxia-sensitive cells in the kidneys control erythropoietin production.
The athletes exercise and reside at intermediate elevations (2,000–3,000 m), which was the pioneering idea in altitude training to promote erythropoiesis by an increase in erythropoietin, which increases erythrocyte volume and improves performance at sea level.
The peritubular cells of the kidney naturally produce erythropoietin, a glycoprotein hormone that promotes the generation of red blood cells. Even though the liver is the primary location of erythropoietin synthesis in the fetus, the kidneys take on this role in adults.
Erythropoietin is frequently misused in endurance sports since research has shown that it can improve performance metrics, including time to exhaustion and maximum oxygen consumption. It increases red blood cell production to promote oxygen absorption and aerobic power, which are utilized to enhance sports performance. However, doing so can be lethal. The additional red blood cells make the blood thicker, increasing the risk of stroke and heart attacks.
The peritubular cells of the kidney naturally produce erythropoietin, a glycoprotein hormone that promotes the generation of red blood cells. Most erythropoietin is produced by peritubular cells in the renal cortex.
Maternal erythropoietin is related to dietary iron status during human pregnancy. Maternal anemia is treated with erythropoietin. Recombinant erythropoietin does not pass the placenta due to the size of the molecule. There was no observed fetal morbidity or death related to the same. As a result, using this treatment during pregnancy is reported to be safe.
Last reviewed at:
19 Jun 2023 - 5 min read
Comprehensive Medical Second Opinion.Submit your Case
Can I take iron injections to rebound my iron levels?
Query: Hello doctor,I have had low iron for quite a while. I also have polycythemia from testosterone supplementation, and at one point, my hematocrit got high enough that I was told to make bi-weekly blood donations. While the hematocrit has been controlled, my iron never rebounded, and I have struggled w... Read Full »
Most Popular Articles
